Evaluate the Efficacy and Safety of TF0023 in Treatments for COVID-19 in Hospitalized Adults

NCT ID: NCT05212818

Last Updated: 2024-01-08

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 19 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-05-10
• Study Completion Date: 2023-03-08

Brief Summary

Techfields Inc. is developing a new investigational prodrug as a topical spray, indicated for relief of the signs and symptoms of ARDS and pneumonia caused by COVID-19. This is a Phase 2, Multicenter, Randomized, Double-blind (Within Dose), Placebo-controlled, Parallel-group, and Dose-range-finding Study to Evaluate the Efficacy and Safety of Active drug Versus Placebo in Treatments for COVID-19 in Hospitalized Adults, relieving of the signs and symptoms of acute respiratory distress syndrome (ARDS) and pneumonia caused by coronavirus disease 2019 (COVID-19).

Detailed Description

A total of approximately 400 eligible patients will be randomly assigned to receive Active Drug low dose (n=80), placebo low dose (n=80), Active Drug high dose (n=160), or placebo high dose (n=80) according to a 1:1:2:1 ratio. The study will be stopped when the last patient completes the double-blind treatment period (end of treatment [EOT]/early termination visit [ETV] on Day 29 + 3 days) and follow-up period. Screening will start when the patient is hospitalized. Each patient enrolled will receive an investigational product (IP; Active Drug or placebo) in a double-blind manner for 28 days (during the double-blind treatment period), starting immediately after all eligibility criteria (including test results) are confirmed. All patients will receive institutional standard of care (SOC) concurrently with their assigned IP. There will be a follow-up visit on Day 36+3 days.

Conditions

COVID-19 Pneumonia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Low Dose of Active Drug

80 patients will be randomly assigned to low dose, take active drug BID.

Group Type: EXPERIMENTAL

TF0023

Intervention Type: DRUG

Techfields Inc. is developing TF0023, a new investigational prodrug, indicated for relief of the signs and symptoms of ARDS and pneumonia caused by COVID-19 and other viruses.

Low Dose Placebo Control

80 patients will be randomly assigned to Low dose placebo, take the placebo BID.

Group Type: EXPERIMENTAL

TF0023

Intervention Type: DRUG

Techfields Inc. is developing TF0023, a new investigational prodrug, indicated for relief of the signs and symptoms of ARDS and pneumonia caused by COVID-19 and other viruses.

High Dose of Active Drug

160 patients will be randomly assigned to high dose, take the active drug BID.

Group Type: EXPERIMENTAL

TF0023

Intervention Type: DRUG

Techfields Inc. is developing TF0023, a new investigational prodrug, indicated for relief of the signs and symptoms of ARDS and pneumonia caused by COVID-19 and other viruses.

High Dose Placebo Control

80 will be randomly assigned to high dose placebo, take the placebo BID.

Group Type: EXPERIMENTAL

TF0023

Intervention Type: DRUG

Techfields Inc. is developing TF0023, a new investigational prodrug, indicated for relief of the signs and symptoms of ARDS and pneumonia caused by COVID-19 and other viruses.

Interventions

TF0023

Techfields Inc. is developing TF0023, a new investigational prodrug, indicated for relief of the signs and symptoms of ARDS and pneumonia caused by COVID-19 and other viruses.

Intervention Type: DRUG

Other Intervention Names

IP, Active drug

Eligibility Criteria

Inclusion Criteria

1. Admitted to a hospital with pulmonary symptoms of active COVID-19.

2. Patient (or legally authorized representative) provides informed consent prior to initiation of any study procedures.

3. Patient (or legally authorized representative) understands and agrees to comply with planned study procedures.

4. Male or nonpregnant female adult ≥18 years of age at time of enrollment.

5. Has laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay (serology is not acceptable) in any specimen, as documented by either of the following:

1. Laboratory confirmed SARS-CoV-2 infection by method as defined above, in sample collected <72 hours prior to randomization; OR

2. Laboratory confirmed SARS-CoV-2 infection by method as defined above, in sample collected ≥72 hours prior to randomization, documented inability to obtain a repeat sample (e.g., due to lack of testing supplies, limited testing capacity, results taking >24 hours, etc.) AND progressive disease suggestive of ongoing SARS-CoV-2 infection.

6. Has a score of 4 (hospitalized, oxygen by mask or nasal prongs), 5 (hospitalized, noninvasive ventilation or high-flow oxygen), or 6 (hospitalized, intubation and mechanical ventilation) in the ordinal scale.

7. Women of childbearing potential must agree to either abstinence or use at least 1 primary form of contraception not including hormonal contraception from the time of screening through Day 29. (Double-barrier method [condoms, sponge, diaphragm, with spermicidal jellies, or cream] is acceptable).

8. Agrees to not participate in another clinical study for the treatment of COVID-19 or SARS-CoV-2 through Day 29. However, Food and Drug Administration (FDA)-approved or under an emergency use authorization antivirus or other drugs may be allowed, and that should be judged by the patient's physician.

Exclusion Criteria

1. Any condition, including any significant medical or neuropsychiatric condition, including the presence of laboratory abnormalities, which in the judgment of the investigator places the patient at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study including, but not limited to:

1. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 × the upper limit of normal (ULN) at screening.

2. Total bilirubin or alkaline phosphatase level >3.0 × the ULN at screening.

3. Platelet count <100 × 109/L.

2. Extracorporeal membrane oxygenation required at baseline.

3. Stage 3 or end stage renal disease (ESRD) patients with acute renal insufficiency may be considered only after discussion with medical monitor.

4. Is at increased risk for bleeding events (e.g., had recent cerebral hemorrhage, gastrointestinal bleeding, serious trauma, recent surgery, or organ biopsy).

5. Pregnant (patient has a positive pregnancy test result at screening) or breast-feeding.

6. Anticipated discharge from the hospital or transfer to another hospital which is not a study site.

7. Allergy to any study medication or known allergy to nonsteroidal anti-inflammatory drugs, including aspirin.

8. Patient must agree to refrain from taking oral aspirin or any orally administered acetylsalicylic acid medications until PK sampling is completed to be eligible to participate in the PK sub-study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Techfields Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Chongxi Yu, Ph.D

Role: STUDY_CHAIR

Techfields Inc

Locations

White Oak Medical Center LLC

Gaithersburg, Maryland, United States

Holy Name Medical Center

Teaneck, New Jersey, United States

Lincoln Medical Center

The Bronx, New York, United States

Worthwhile Clinical Trial

Benoni, Gauteng, South Africa

Dr JM Engelbrecht Trials Site

Somerset West, Western Cape, South Africa

Countries

United States; South Africa

Other Identifiers

TF-TF0023-201

Identifier Type: -

Identifier Source: org_study_id